Passive Leg Raise and Mini-fluid Challenge Effect on Various Cardiac Output Surrogates for Fluid Responsiveness

Fluid Responsiveness Clinical Trial

— PHOENIX  

Official title:

Passive Leg Raise and Mini-fluid Challenge Effect on Various Cardiac Output Surrogates Such as Pulse Pressure Variation (PPV), End-tidal CO2 (Carbon Dioxide), Bioreactance (Stroke Volume Index -SVI) and Velocity Time Integral on Echocardiographic Exam for Fluid Responsiveness in Patients With Moderately Severe ARDS (Acute Respiratory Distress Syndrome)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06390423
• Other study ID #: RAMPHOENIX
• Status: Recruiting
• Start date: July 1, 2023
• Est. completion date: June 2024

Study information

• Verified date: April 2024
• Source: CentraCare
• Contact: Ramakanth Pata
• Phone: 320-240-2207
• Email: cookybrey1[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In the critically ill population, fluid administration in an unstable patient is perhaps the most common intervention that is performed. Uncorrected hypovolemia with inappropriate vasopressors lead to organ hypoperfusion where as overzealous fluid administration especially in ARDS (Adult respiratory distress syndrome) can increase mortality. It has been estimated that only 50% of hemodynamically unstable critically ill patients are volume responsive, hence dynamic assessment of preload responsiveness has been proposed to better identify those individuals who would benefit from fluid bolus.

Description:

Fluid responsiveness in patients with moderate to severe ARDS is crucial, as additional unnecessary fluid may be harmful. Various techniques of hemodynamic assessment exist, each with its own advantages and limitations. This study compares different techniques of preload responsiveness that include passive leg raise (PLR) and mini-fluid challenge induced changes in Pulse pressure variation (PPV), End tidal CO2, Bioreactance based Stroke volume index (SVI) and velocity time integral (VTI) on Echocardiogram.

Study protocol :

Baseline Echo with VTI will be obtained Bed side monitor will be set to display PPV and end tidal CO2 Baxter Starling system will be connected to the patient All baseline values will be recorded Tidal volume will be temporarily adjusted to 8 ml/kg , which will be reverted back to 6ml/kg after the measurements. This has proven to be a safe maneuver.

All the above hemodynamic assessments will be performed for eligible patients by measuring before and after PLR and repositioning to baseline. VTI will be estimated by bed side Echocardiogram. SVI will be estimated using the Starling system (Baxter). PPV and End tidal CO2 will be recorded from the bed side monitors.

Fluid responsiveness is presumed with a change in VTI of 10%. For these patients a mini-fluid challenge of 250 cc of crystalloids (NS, RL or Normosol) will be given over 10 min and PPV, VTI, End tidal CO2 and SVI will be recorded before and after fluid challenge. Patients with VTI change of < 10%, as non-responders, who will also be included in the analysis for assessment of reliability using the ROC curves. hemodynamic assessments and repeated fluid challenge will be considered as needed. Stability of vasopressor dose with maximum of 500 cc of crystalloid will be considered as positive fluid responder. This cohort of patients will be considered as gold standard for preload responsiveness and will be categorized based on a nominal scale. Patients who need higher vasopressor support despite 1L of crystalloid within 3 hours will be considered fluid non-responders.

Data collection:

De-identified data will be recorded. Age, BMI ( body mass index), Charleston co-morbidity index, baseline PPV, End-tidal CO2, SVI, VTI, post PLR, post fluid challenge, return to baseline, PF ratio, PEEP (positive end-expiratory pressure), SOFA (sequential organ function assessment) Score on the day of the test will be recorded.

Statistical Analysis:

Microsoft Excel will be used to record data on an institutional computer. Once the data is collected, it will be exported for statistical analysis. Jamovi will be utilized for statistical analysis. Baseline characteristics will be compared using a T-test if normative distribution or non-parametric test such as Mann Whitney U test. Reliability and accuracy will be detected using ROC curve assessment. In addition, the Youden index approach will be utilized to identify cut-offs of each of the variables and their change. (PPV, SVI,VTI and End tidal CO2). All the delta values will be compared with pearson correlation with a scatter plot and line of identity. Agreement between variables will be done using Bland-Altman analysis. If necessary, values will be transformed into Z scores. For all comparisons, a p-value of <0.05 was considered significant.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 64
• Est. completion date: June 2024
• Est. primary completion date: June 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 90 Years

Eligibility

Inclusion Criteria:

• Age between 30 - 90 years

• Diagnosis of Vasodilatory Shock with no other obvious cause of hypotension

• Diagnosis of ARDS with PF ratio < 150 , PEEP > 8

• Patients who are under paralysis or deeply sedated, on a mechanical ventilator

Exclusion Criteria:

• Patients with arrhythmias including atrial fibrillation

• Patients with chest tube, intra-abdominal hypertension or with its risk factors

• Patients with structural heart disease including pulmonary hypertension (RVSP > 45) and heart failure

• Patients on extracorporeal support such as ECMO, CRRT or MCS.

• Patients with COPD with a premorbid FEV1 < 1.5 L

• Severe atherosclerotic vascular disease

Related Conditions & MeSH terms

• Fluid Responsiveness

Intervention

Diagnostic Test:
• Passive leg raise, SVI via bioreactance, Echo based VTI
No interventions other than fluid challenge

Locations

Country	Name	City	State
United States	St Cloud Hospital	Saint Cloud	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
CentraCare

Country where clinical trial is conducted

United States, 

References & Publications (2)

Monnet X, Bataille A, Magalhaes E, Barrois J, Le Corre M, Gosset C, Guerin L, Richard C, Teboul JL. End-tidal carbon dioxide is better than arterial pressure for predicting volume responsiveness by the passive leg raising test. Intensive Care Med. 2013 Jan;39(1):93-100. doi: 10.1007/s00134-012-2693-y. Epub 2012 Sep 19. — View Citation

Monnet X, Teboul JL. Passive leg raising: five rules, not a drop of fluid! Crit Care. 2015 Jan 14;19(1):18. doi: 10.1186/s13054-014-0708-5. No abstract available. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Vasopressor dose in Nor-epinephrine equivalents (NE) measured as mcg/kg/min	We shall assess the need for vasopressor dose e.g nor-epinephrine dose. If the dose remains constant after fluid bolus until 3 hours, we shall consider them fluid resposive. If the dose requirement goes up despite fluid bolus, we shall label them fluid un-responsive	3 hours after the initial passive leg raise